HOTAIR |
Breast |
Gupta et al. (2010), Bhan et al. (2013), Wang et al. (2013)
|
Oncogene |
Predictor of metastasis and poor survival |
|
Liver |
Geng et al. (2011), Yang et al. (2011), Ishibashi et al. (2013)
|
Oncogene |
Predictor of recurrence and poor survival |
|
Colorectal |
Kogo et al. (2011) |
Oncogene |
Predictor of liver metastasis and pool survival |
|
Gastric |
Hajjari et al. (2013) |
Oncogene |
Predictor of lymph node metastasis |
|
Pancreas |
Kim et al. (2013) |
Oncogene |
Predictor of poor survival |
|
Lung |
Liu et al. (2013a), Nakagawa et al. (2013)
|
Oncogene |
Predictor of metastasis and poor survival |
|
Esophagus |
Lv et al. (2013) |
Oncogene |
Predictor of metastasis and poor survival |
|
Cervical |
Huang et al. (2014) |
Oncogene |
Predictor of metastasis and poor survival |
MALAT1 |
Lung adenocarcinoma |
Ji et al. (2003), Gutschner et al. (2013)
|
Oncogene |
Predictor of metastasis and poor survival |
|
Liver |
Lai et al. (2012) |
Oncogene |
Predictor of recurrence after liver transplantation |
|
Colorectal |
Zheng et al. (2014) |
Oncogene |
Predictor of poor postoperative prognosis |
|
Cervical |
Guo et al. (2010) |
Oncogene |
|
|
Bladder |
Ying et al. (2012), Han et al. (2013)
|
Oncogene |
Predictor of metastasis |
|
Uterine |
Yamada et al. (2006) |
Oncogene |
|
|
Osteosarcoma |
Fellenberg et al. (2007) |
Oncogene |
Predictor of poor response to chemotherapy |
H19 |
Esophagus |
Hibi et al. (1996) |
Oncogene |
|
|
Breast |
Lottin et al. (2002) |
Oncogene |
|
|
Lung |
Kondo et al. (1995) |
Oncogene |
|
|
Bladder |
Ariel et al. (2000) |
Oncogene |
|
|
Ovarian |
Kim et al. (1998) |
Oncogene |
|
|
Cervical |
Kim et al. (2002) |
Oncogene |
|
|
Osteosarcoma |
Ulaner et al. (2003) |
Oncogene |
|
|
Neck squamous carcinoma |
el-Naggar et al. (1999) |
Oncogene |
|
|
Liver |
Matouk et al. (2007) |
Oncogene |
|
ncRAN |
Neuroblastoma |
Bown et al. (1999), Yu et al. (2009)
|
Oncogene |
Predictor of poor survival |
|
Bladder |
Zhu et al. (2011) |
Oncogene |
|
|
Colorectal |
Qi et al. (2014) |
Tumor suppressor |
Low level predicts poor survival |
HULC |
Liver |
Panzitt et al. (2007), Matouk et al. (2009), Liu et al. (2012)
|
Oncogene |
Diagnostics |
GAS5 |
Breast |
Mourtada-Maarabouni et al. (2009) |
Tumor suppressor |
|
|
Kidney |
Qiao et al. (2013) |
Tumor suppressor |
|
|
Pancreas |
Lu et al. (2013) |
Tumor suppressor |
|
|
Bladder |
Liu et al. (2013b) |
Tumor suppressor |
|
|
Lung |
Shi et al. (2013) |
Tumor suppressor |
|
|
Gastric |
Sun et al. (2014) |
Tumor suppressor |
Low level predicts poor prognosis |
|
Pleural mesothelioma |
Renganathan et al. (2014) |
Tumor suppressor |
Low level predicts poor prognosis |
|
Liver |
Tu et al. (2014) |
Tumor suppressor |
Low level predicts poor prognosis |
PCA3 |
Prostate |
Bussemakers et al. (1999), Hessels et al. (2003)
|
Oncogene |
Non-invasive diagnosis by sampling urine or blood |
|
|
|
|
Tinzl et al. (2004), Lee et al. (2011)
|
|
|
UCA1 |
Bladder |
Wang et al. (2006) |
Oncogene |
Non-invasive diagnosis by sampling urine |
PCGEM1 |
Prostate |
Petrovics et al. (2004) |
Oncogene |
High risk predictor |
PRNCR1 |
Prostate |
Chung et al. (2011) |
Oncogene |
High risk predictor |
MEG3 |
Leukemia |
Benetatos et al. (2010) |
Tumor suppressor |
CpG methylation predicts poor survival |
|
Pituitary adenoma |
Gejman et al. (2008) |
Tumor suppressor |
|
|
Meningioma |
Zhang et al. (2010) |
Tumor suppressor |
Loss associated with progression |
|
Glioma |
Wang et al. (2012) |
Tumor suppressor |
|
NBAT-1 |
Neuroblastoma |
Pandey et al. (2014) |
Tumor suppressor |
Loss associated with progression |
LincRNA–ROR |
Liver |
Takahashi et al. (2014) |
Oncogene |
Diagnostics by sampling cancer exosomes; indicator of chemoresistance |
PCAT1 |
Prostate |
Prensner et al. (2011) |
Oncogene |
Associated with progression |